uniQure N.V. Files 8-K Report

TL;DR

uniQure filed an 8-K, mostly routine stuff, check financials.

AI Summary

On November 21, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclosures detailed in the provided text. The report confirms uniQure's status as a Netherlands-based company operating in the pharmaceutical preparations sector.

Why It Matters

This 8-K filing serves as a routine disclosure for uniQure N.V., indicating compliance with regulatory requirements for reporting financial statements and exhibits.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, indicating no immediate material adverse events.

Key Players & Entities

• uniQure N.V. (company) — Registrant
• November 21, 2024 (date) — Date of Report
• The Netherlands (location) — Jurisdiction of Incorporation
• 2834 (other) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Filing Documents

• qure-20241121x8k.htm (8-K) — 34KB
• qure-20241121xex99d1.htm (EX-99.1) — 19KB
• qure-20241121xex99d1001.jpg (GRAPHIC) — 5KB
• 0001558370-24-015883.txt ( ) — 180KB
• qure-20241121.xsd (EX-101.SCH) — 3KB
• qure-20241121_lab.xml (EX-101.LAB) — 15KB
• qure-20241121_pre.xml (EX-101.PRE) — 10KB
• qure-20241121x8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 21, 2024, uniQure N.V. (the " Company ") issued a press release announcing the dosing of the first patient in the Company's Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of uniQure N.V. dated November 21, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIQURE N.V. Date: November 21, 2024 By: /s/ Jeannette Potts JEANNETTE POTTS Chief Legal and Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR